Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics
Executive Summary
FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar
You may also be interested in...
ANDA Exclusivity Protected From Patent Delisting Under Appeals Court Ruling
Generic companies will no longer lose 180-day marketing exclusivity solely because a brand name company delists a patent they have challenged
ANDA Exclusivity Protected From Patent Delisting Under Appeals Court Ruling
Generic companies will no longer lose 180-day marketing exclusivity solely because a brand name company delists a patent they have challenged
The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills
The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009